Identifying a structural misalignment between clinical user journeys and product architecture before the next build cycle began
A $15M healthcare IT product portfolio serving clinical operations was entering its next product roadmap planning cycle. Standard product discovery had been completed — stakeholder interviews, requirements documentation, feature prioritisation — and the team was preparing to commit engineering capacity. The problem was the discovery method: in compliance-sensitive clinical environments, stakeholder interviews consistently capture the official workflow protocol, not the operational reality.
Direct field observation and contextual inquiry sessions — conducted with clinical staff during actual task execution, not interviews — revealed a layered system of compensating behaviours the requirements had not captured. Staff had developed informal routing protocols, manual reconciliation steps across systems, and shadow processes normalised over time.
End-to-end service blueprinting mapped frontstage user actions, backstage clinical processes, system touchpoints, and failure points in a single view. The blueprint made the product problem visible: the architecture had structurally diverged from the actual user journey. Every feature on the roadmap was being scoped on top of a misaligned foundation.
The workflow gap analysis and service blueprint were presented to product and engineering leadership before sprint planning or architecture commitment. The case was built on observed evidence — specific user journey steps, named failure points, frequency of compensating behaviours — not stakeholder preference. A future-state experience model was designed to resolve the structural misalignment, redefining the product's core architecture requirements.
Roadmap halted. Architecture direction reversed. The portfolio was redirected before additional build investment was committed — a product governance decision, not a UX iteration.
The $15M portfolio was redirected to build on a workflow foundation aligned with actual clinical user journeys. Downstream re-architecture was eliminated before it could be incurred. Accountable for the outcome through direct product leadership partnership — not delivered as an advisory recommendation and handed off.